title: Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas.
abstract: OBJECTIVE
  To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas.
  
  
  METHODS
  We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15-35 patients with advanced or metastatic esophageal and GEJ carcinomas.
  
  
  RESULTS
  10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m(2).
authors.affiliation: a Division of Hematology and Oncology, University of Arizona Cancer Center , Tucson , AZ , USA.
authors.forename: Emad
authors.initials: E
authors.lastname: Elquza
authors.affiliation: a Division of Hematology and Oncology, University of Arizona Cancer Center , Tucson , AZ , USA.
authors.forename: Hani M
authors.initials: HM
authors.lastname: Babiker
authors.affiliation: b Department of Radiation Oncology , University of Arizona , Tucson , AZ , USA.
authors.forename: Krisha J
authors.initials: KJ
authors.lastname: Howell
authors.affiliation: c Department of Medicine , University of Arizona , Tucson , AZ , USA.
authors.forename: Andrew I
authors.initials: AI
authors.lastname: Kovoor
authors.affiliation: d Swedish Cancer Institute , Seattle , WA , USA.
authors.forename: Thomas David
authors.initials: TD
authors.lastname: Brown
authors.affiliation: a Division of Hematology and Oncology, University of Arizona Cancer Center , Tucson , AZ , USA.
authors.forename: Hitendra
authors.initials: H
authors.lastname: Patel
authors.affiliation: a Division of Hematology and Oncology, University of Arizona Cancer Center , Tucson , AZ , USA.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Malangone
authors.affiliation: e Division of Hematology and Oncology, Mayo Clinic , Scottsdale , AZ , USA.
authors.forename: Mitesh J
authors.initials: MJ
authors.lastname: Borad
authors.affiliation: f Banner MD Anderson Cancer Center , Gilbert , AZ , USA.
authors.forename: Tomislav
authors.initials: T
authors.lastname: Dragovich
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001130:Arizona; D002277:Carcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016629:Esophagectomy; D004943:Esophagogastric Junction / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects*; D005260:Female; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D000068437:Pemetrexed / Q000008:administration & dosage* / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000068437:Pemetrexed; D002945:Cisplatin
keywords: Pemetrexed; cisplatin; gastroesophageal carcinoma; radiation